Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Jiangsu Alphamab Biopharmaceuticals Co. Ltd. is currently engaged in the prosecution of 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed in 2 distinct art units, which suggests that the company's pharmaceutical developments are categorized under different technical specialties. The presence of 2 distinct examiners indicates that the company must manage 2 separate examination styles and timelines. This distribution of 2 pending office actions across different reviewers prevents the portfolio from being entirely dependent on a single individual.
The busiest examiner for this portfolio is VAN DRUFF, SYDNEY, who is responsible for 1 busiest examiner pending office action. This 1 busiest examiner pending office action is part of the 2 pending office actions currently active for the company. Because the workload is split between 2 distinct examiners and 2 distinct art units, the company's patent strategy involves multiple independent review processes. For a practitioner, this requires a coordinated approach to ensure consistency across 2 distinct art units in the Biotechnology & Pharmaceuticals sector. The presence of 2 pending office actions indicates an active and diversified effort to secure intellectual property rights.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN DRUFF, SYDNEY | 1 | 55.0% | +31.7% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18454006 | A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR | VAN DRUFF, SYDNEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769544 | OX40/PD-L1 BISPECIFIC ANTIBODY | LEE, YIE CHIA | 33d |
| 18454006 | A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR | VAN DRUFF, SYDNEY | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18454006 | A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR | VAN DRUFF, SYDNEY | 1643 | §103§112 | Non-Final OA | — | Pending | Aug 22, 2023 |
| 17769544 | OX40/PD-L1 BISPECIFIC ANTIBODY | LEE, YIE CHIA | 1642 | §103Other | Final Rejection | 33d | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial